United Therapeutics Corporation (UTHR)

Oncology Corporate Profile

Stock Performance

140.5000
0.0000

HQ Location

1040 Spring Street
Silver Spring, MD 20910

Company Description

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have four approved products on the market today and we are not stopping there! From the United States to Europe to the Asia Pacific, we are proud of our multicultural business environment where employees can collaborate with people all over the world. As a group, we are relentless in our pursuit of “medicines for life”® and continue our research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.

Website: http://www.unither.com

Brand Generic Indication
Unituxin_?dinutuximabUnituxin_? is an antibody that binds to the surface of neuroblastoma cells. Unituxin is being approved for use as part of a multimodality regimen, including surgery, chemotherapy and radiation therapy for patients who achieved at least a partial response to prior first-line multiagent, multimodality therapy.

This company does not have any pipeline products

Source


http://www.unither.com

Recent News Headlines

How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma

3/20/2017 11:02 am

[PR Newswire] - Last Friday, shares in La Jolla, California headquartered Orexigen Therapeutics Inc. ended the session 3.76% lower at $4.10. The stock recorded a trading volume of 182,389 shares. The Company's shares have surged 141.18% in the previous three months and 135.63% on an YTD basis.

Northwell Health and United Therapeutics Announce Strategic Partnership to Advance Bioelectronic Medicine and Cell Therapy

3/9/2017 11:00 am

[PR Newswire] - "Collaboration is the indispensable factor in successful medical research," said Kevin J. Tracey, M.D., President and CEO of the Feinstein Institute. "With great partners, you can accomplish great things for science and for patients.

United Therapeutics Corporation To Present At Barclays Global Healthcare Conference

3/7/2017 11:00 am

[PR Newswire] - SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 7, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive ...

United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference

2/28/2017 11:00 am

[PR Newswire] - SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive ...

United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results

2/22/2017 11:00 am

[PR Newswire] - SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended ...

United Therapeutics Corporation To Report Fourth Quarter And Annual 2016 Financial Results Before The Market Opens On Wednesday, February 22, 2017

2/15/2017 11:00 am

[PR Newswire] - SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its fourth quarter and annual 2016 ...